01734nas a2200361   4500000000100000008004100001260001300042653001500055653001000070653001000080653002100090653001900111653002800130653003300158653003000191653001100221653001100232653002300243653001200266653000900278653001600287653001700303653002400320100001200344700002000356245007700376856005900453300001100512490000700523050003200530520079600562022001401358       1989                            d  c1989 Dec10aAdolescent10aAdult10aChild10aChild, Preschool10aCohort Studies10aCross-Sectional Studies10aDrug Administration Schedule10aDrug Therapy, Combination10aFemale10aHumans10aLeprostatic Agents10aleprosy10aMale10aMiddle Aged10aTime Factors10aTrinidad and Tobago1 aSuite M1 aEdinborough N B00aA second report on multidrug therapy for leprosy in Trinidad and Tobago.  uhttp://leprev.ilsl.br/pdfs/1989/v60n4/pdf/v60n4a07.pdf  a288-990 v60  aInfolep Library - available3 a<p>Multidrug therapy consisting of rifampicin, clofazimine and dapsone, was introduced to Trinidad and Tobago in January 1982. This was with slight modification of the WHO regimens. Since then 717 patients have completed multidrug therapy up to the end of December 1987. Of these, 272 patients have completed surveillance and have been discharged from clinic attendance. Thirty-four patients died before completing surveillance and three are known to have migrated. Of the remaining 408 cases still under surveillance, the majority are multibacillary. This paper reviews the outcome of multidrug therapy in Trinidad and Tobago between January 1982 and December 1987--a period of 6 years, and presents some of the statistics related to the newly diagnosed patients within the same period.</p>  a0305-7518